Transgender patients with end-stage renal disease (ESRD) present with specific challenges during the transplant evaluation, perioperative management, and postoperative phase of care. Demographic information, health-care records, chosen name, and gender identity along with documentation of specific health-care needs can become a challenge when gender assigned at birth is incongruent with the patients gender identity. Medical care involves addressing the end-organ disease as well as addressing those aspects of care specific to the transgender patient. This review article provides information on defining transgender, the impact of ESRD, and transgender in the transplant process and considerations in the throughout phases of care. Current recommendations for management of this unique population are provided.
Association AP. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association; 1995: ed2000.
6.
Force APADT. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013:913.
7.
SaferJD. Transgender medical research, provider education, and patient access are overdue. Endocrine practice: official journal of the American College of Endocrinology and the AmericanAssoc Clin Endocrinol. 2013;19(4):575–576.
8.
Prevention CfDCa. Summary Health Statistics for U.S. Adults: National Health Interview Survey. U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for Health Statistics: Hyattsville, MD; 2012.
9.
TuttleKRBakrisGLBilousRW. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014;64(4):510–533.
10.
National Institutes of Health NIoDaDaKD, United States Renal Data System. 2014 USRDS Annual Data Report: An Overview of the Epidemiology of Kidney Disease in the United States. Bethesda, MD: United States Renal Data System; 2014.
11.
KesslerMFrimatLPanescuVBrianconS. Impact of nephrology referral on early and midterm outcomes in ESRD: EPidemiologie de l’Insuffisance REnale chronique terminale en Lorraine (EPIREL): results of a 2-year, prospective, community-based study. Am J Kidney Dis. 2003;42(3):474–485.
12.
GatesGJ. Demographics and LGBT health. J Health Soc Behav. 2013;54(1):72–74.
13.
WichinskiKA. Providing culturally proficient care for transgender patients. Nursing. 2015;45(2):58–63.
14.
RotondiNKBauerGRScanlonKKaayMTraversRTraversA. Nonprescribed hormone use and self-performed surgeries: “do-it-yourself” transitions in transgender communities in Ontario, Canada. Am J Public Health. 2013;103(10):1830–1836.
15.
WierckxKElautEDeclercqE. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol. 2013;169(4):471–478.
16.
BellH.Falling through the cracks. Health insurance policies increasingly include coverage for treatments related to gender dysphoria, but gaps remain. Minn Med. 2013;96(8):18–22.
17.
BocktingWORobinsonBEForbergJScheltemaK. Evaluation of a sexual health approach to reducing HIV/STD risk in the transgender community. AIDS Care. 2005;17(3):289–303.
18.
FeldmanJGoldbergJ. Transgender Primary Medical Care: Suggested Guidelines for Clinicians in British Columbia. Vancouver, BC: Vancouver Coastal Health, Transgender Health Program; 2006.
19.
World Professional Association for Transgender Health. World Professional Association for Transgender Health Standards of Care: Version 7. Washington, DC: World Professional Association for Transgender Health: 2012: 1–109.
20.
HembreeWC1Cohen-KettenisPDelemarre-van de WaalHA. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009;94(9):3132–3154.
MuradMHElaminMBGarciaMZ. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin Endocrinol. 2010;72(2):214–231.
23.
MichelAMormontCLegrosJJ. A psycho-endocrinological overview of transsexualism. Eur J Endocrinol. 2001;145(4):365–376.
24.
WarringtonTPBostwickJM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81(10):1361–1367.
25.
GamarelKEReisnerSLLaurenceauJPNemotoTOperarioD. Gender minority stress, mental health, and relationship quality: a dyadic investigation of transgender women and their cisgender male partners. J Fam Psychol. 2014;28(4):437–447.
26.
ChapmanJRWebsterACWongG. Cancer in the transplant recipient. Cold Spring Harbor Perspect Med. 2013;3(7):.
27.
AschWSBiaMJ. Oncologic issues and kidney transplantation: a review of frequency, mortality, and screening. Adv Chronic Kidney Dis. 2014;21(1):106–113.
28.
HageJJDekkerJJKarimRBVerheijenRHBloemenaE. Ovarian cancer in female-to-male transsexuals: report of two cases. Gynecol Oncol. 2000;76(3):413–415.
29.
Bazarra-CastroM SCFuldaSKlotsheJPieperLWittchenHKarlG. Comorbidities in transsexual patients under homronal treatment compared to age- and gender- matched primary care comparison groups. Reprod Syst Sex Disord. 2012;1(1):1–4.
30.
KasiskeBLSnyderJJGilbertsonDMatasAJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplantat. 2003;3(2):178–185.
31.
ChakkeraHAMandarinoLJ. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation. 2013;95(5):647–652.
32.
StreeterNB. Considerations in prevention of surgical site infections following cardiac surgery: when your patient is diabetic. J Cardiovasc Nurs. 2006;21(3):E14–E20.
